Baader Bank Aktiengesellschaft Has $1.72 Million Holdings in Amgen Inc. $AMGN

Key Points

• Baader Bank Aktiengesellschaft increased its holdings in Amgen by 562.0% during the 2nd quarter, acquiring an additional 5,238 shares bringing their total to 6,170 shares worth $1.72 million.
• Institutional investors now own 76.50% of Amgen's stock, with other notable increases in holdings from firms like Vanguard Group and Royal Bank of Canada during the 1st quarter of this year.
• Amgen recently paid a quarterly dividend of $2.38 per share, which has resulted in an annualized yield of 3.5% and a payout ratio of 77.84%.

Baader Bank Aktiengesellschaft grew its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 562.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,170 shares of the medical research company's stock after buying an additional 5,238 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in Amgen were worth $1,723,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen during the first quarter valued at $25,000. First Pacific Financial boosted its stake in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after acquiring an additional 67 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its stake in shares of Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after acquiring an additional 85 shares during the last quarter. Pinney & Scofield Inc. acquired a new stake in Amgen in the 4th quarter worth about $26,000. Finally, Activest Wealth Management boosted its stake in Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after buying an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.69% of the company's stock.

Amgen Price Performance

Shares of AMGN traded up $0.59 during midday trading on Monday, reaching $286.00. The stock had a trading volume of 3,050,077 shares, compared to its average volume of 2,339,546. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $339.17. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The firm's 50 day moving average price is $290.35 and its 200-day moving average price is $290.02. The company has a market capitalization of $153.97 billion, a P/E ratio of 23.39, a P/E/G ratio of 2.48 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. Amgen's payout ratio is 77.84%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMGN. Wall Street Zen lowered Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Piper Sandler raised their target price on Amgen from $328.00 to $342.00 and gave the company an "overweight" rating in a report on Monday, August 25th. William Blair reiterated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Bank of America raised their target price on Amgen from $252.00 to $261.00 and gave the company an "underperform" rating in a report on Wednesday, July 23rd. Finally, Citigroup raised their target price on Amgen from $305.00 to $310.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus target price of $304.43.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.